Literature DB >> 6328529

RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day.

R C Gaillard, A Riondel, A F Muller, W Herrmann, E E Baulieu.   

Abstract

RU 486 is a synthetic steroid hormone antagonist which acts at the receptor level. It has both intrinsic anti-progesterone and antiglucocorticosteroid properties in animals. We investigated the antiglucocorticosteroid activity in humans by evaluating the pituitary-adrenal response to RU 486 in men and in pregnant and nonpregnant women. In non-pregnant women, RU 486 (approximately equal to 1 mg/kg of body weight per day) produced an interruption of the luteal phase without affecting the pituitary-adrenal axis, thereby indicating a more potent anti-progesterone than antiglucorticosteroid effect. In the course of pregnancy interruption by RU 486 (approximately equal to 4 mg/kg per day), there was a significant increase in plasma corticotropin, beta-lipotropin, and cortisol concentrations. In normal men, RU 486 administration led to a dose-dependent stimulation of plasma corticotropin, beta-endorphin, and cortisol. This disinhibition of the pituitary-adrenal axis was only observed during the morning hours of the circadian rhythm. When administered concomitantly with 1 mg of dexamethasone at midnight, 6 mg of RU 486 per kg completely suppressed the dexamethasone inhibitory effect on the pituitary-adrenal axis. These results indicate that RU 486 is an antiglucocorticosteroid that disrupts the negative pituitary feedback of both the morning cortisol rise and administered dexamethasone. Furthermore, they demonstrate the possibility of optimizing the anti-progestational effect of the compound and its potential use for human fertility control by modifying the dose and the time of administration of the drug and thereby minimizing the antiglucocorticosteroid effect.

Entities:  

Keywords:  Abortion, Induced; Adrenal Cortex Hormones--men; Adrenal Cortex Hormones--women; Biology; Dexamethasone Acetate; Endocrine System; Examinations And Diagnoses; Family Planning; Fertility Control, Postconception; Hormone Antagonists--administraction and dosage; Hormones; Laboratory Examinations And Diagnoses; Laboratory Procedures; Menstrual Cycle--changes; Menstruation; Physiology; Pituitary Gland; Reproduction; Reproductive Control Agents

Mesh:

Substances:

Year:  1984        PMID: 6328529      PMCID: PMC345325          DOI: 10.1073/pnas.81.12.3879

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  11 in total

1.  DIAGNOSIS OF CUSHING'S SYNDROME; SINGLE DOSE DEXAMETHASONE SUPPRESSION TEST.

Authors:  C A NUGENT; T NICHOLS; F H TYLER
Journal:  Arch Intern Med       Date:  1965-08

2.  A rapid method for measuring 17-hydroxycorticosteroids in urine.

Authors:  M G METCALF
Journal:  J Endocrinol       Date:  1963-06       Impact factor: 4.286

3.  Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome.

Authors:  G W LIDDLE
Journal:  J Clin Endocrinol Metab       Date:  1960-12       Impact factor: 5.958

4.  A radioimmunoassay for rat plasma ACTH.

Authors:  L H Rees; D M Cook; J W Kendall; C F Allen; R M Kramer; J G Ratcliffe; R A Knight
Journal:  Endocrinology       Date:  1971-07       Impact factor: 4.736

5.  [Determination by competition of plasma corticol. Modification of Murphy's method].

Authors:  R Leclercq; G Copinschi; J R Franckson
Journal:  Rev Fr Etud Clin Biol       Date:  1969-10

6.  Inhibition of glucocorticosteroid action in cultured L-929 mouse fibroblasts by RU 486, a new anti-glucocorticosteroid of high affinity for the glucocorticosteroid receptor.

Authors:  I Jung-Testas; E E Baulieu
Journal:  Exp Cell Res       Date:  1983-08       Impact factor: 3.905

7.  A specific radioimmunoassay for human beta-lipotropin.

Authors:  W J Jeffcoate; L H Rees; P J Lowry; G M Besser
Journal:  J Clin Endocrinol Metab       Date:  1978-07       Impact factor: 5.958

8.  [The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy].

Authors:  W Herrmann; R Wyss; A Riondel; D Philibert; G Teutsch; E Sakiz; E E Baulieu
Journal:  C R Seances Acad Sci III       Date:  1982-05-17

9.  beta-Endorphin in human cerebrospinal fluid.

Authors:  W J Jeffcoate; L H Rees; L McLoughlin; S J Ratter; J Hope; P J Lowry; G M Besser
Journal:  Lancet       Date:  1978-07-15       Impact factor: 79.321

10.  DNA binding properties of glucocorticosteroid receptors bound to the steroid antagonist RU-486.

Authors:  S Bourgeois; M Pfahl; E E Baulieu
Journal:  EMBO J       Date:  1984-04       Impact factor: 11.598

View more
  34 in total

1.  Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.

Authors:  Victoria Wargon; Marina Riggio; Sebastián Giulianelli; Gonzalo R Sequeira; Paola Rojas; María May; María L Polo; María A Gorostiaga; Britta Jacobsen; Alfredo Molinolo; Virginia Novaro; Claudia Lanari
Journal:  Int J Cancer       Date:  2014-11-12       Impact factor: 7.396

2.  Clinical pharmacokinetics of mifepristone.

Authors:  O Heikinheimo
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 3.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Effects of RU 486 and tamoxifen on cocaine-induced behavioral and endocrinologic activations in male and female Fischer rats.

Authors:  Hui-Bing Katie Wu; Tipyamol Niyomchai; Eugene Festa; AnaChristina E Minerly; Karen Weierstall; Deirtra Hunter; Weilun Sun; Jan Weiner; Shirzad Jenab; Vanya Quinones-Jenab
Journal:  Ethn Dis       Date:  2008       Impact factor: 1.847

Review 5.  Contragestion by antiprogestin RU 486: a review.

Authors:  E E Baulieu; A Ulmann; D Philibert
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

Review 6.  New aspects of progesterone interactions with the actin cytoskeleton and neurosteroidogenesis in the cerebellum and the neuronal growth cone.

Authors:  Lisa Wessel; Laura Olbrich; Beate Brand-Saberi; Carsten Theiss
Journal:  J Histochem Cytochem       Date:  2014-08-20       Impact factor: 2.479

Review 7.  Medical therapy of Cushing's disease.

Authors:  Lynnette K Nieman
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 8.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

9.  Mifepristone pretreatment reduces ethanol withdrawal severity in vivo.

Authors:  Lynda Sharrett-Field; Tracy R Butler; Jennifer N Berry; Anna R Reynolds; Mark A Prendergast
Journal:  Alcohol Clin Exp Res       Date:  2013-03-25       Impact factor: 3.455

10.  Chronic blockade of hindbrain glucocorticoid receptors reduces blood pressure responses to novel stress and attenuates adaptation to repeated stress.

Authors:  Andrea G Bechtold; Gina Patel; Guenther Hochhaus; Deborah A Scheuer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-03-11       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.